Mirati Therapeutics - Pappas Capital

Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocetinostat in Bladder Cancer Patients with Genetic Alterations of CREBBP and EP300

SAN DIEGO, Jan. 7, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in a Phase 2 clinical trial designed to evaluate the efficacy, safety and pharmacokinetics of mocetinostat as a treatment for a select group of patients with bladder cancer. The trial will enroll patients whose tumors have mutations or deletions of the CREBBP and/or EP300 genes.

Mirati Therapeutics - 01/07/2015

Mirati Therapeutics Doses First Patient in Investigator-Sponsored Phase 2 Study of Mocetinostat in Non-Hodgkin's Lymphoma

Study to focus on mutations and deletions of CREBBP and EP300 genes in lymphomas

SAN DIEGO, Jan. 6, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Memorial Sloan Kettering Cancer Center in New York has dosed the first patient in an investigator-sponsored Phase 2 clinical trial of mocetinostat in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The trial will enroll patients whose tumors have mutations or deletions of the CREBBP and/or EP300 genes.

Mirati Therapeutics - 01/06/2015

Mirati Therapeutics Doses First Patient in Expansion Cohorts of Phase 1b Trial of MGCD265 in Genetically Selected Patients

Study Seeks to Confirm a High Response Rate among Cancer Patients with MET and Axl Genetic Alterations
SAN DIEGO, Dec. 23, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD265 in selected patients exhibiting genetic alterations of MET or Axl. In this segment of the study, one of the expansion cohorts will enroll patients with NSCLC and another will enroll patients with other solid tumors. Both cohorts will enroll only those patients that have specific MET driver mutations including MET gene point mutations, gene amplification, and MET or Axl gene rearrangements.

Mirati Therapeutics - 12/23/2014

Michael Grey Joins Mirati Therapeutics Board of Directors

Michael Grey Joins Mirati Therapeutics Board of Directors

SAN DIEGO, Nov. 6, 2014 /PRNewswire/ --- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran Michael Grey has joined its board of directors.

"Mike's extensive experience in the pharmaceutical and biotechnology industries, including senior leadership and board positions in several successful companies, will complement and strengthen our Board," said Charles M. Baum, M.D. Ph.D., president and CEO of Mirati. "His expertise in developing strategy, identifying growth opportunities and building organizations is invaluable as we advance our targeted oncology medicines to the market."

Mirati Therapeutics - 11/06/2014

Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma

SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell lymphoma (DLBCL). In June, mocetinostat was granted Orphan Drug Designation as a treatment for myelodysplastic syndrome (MDS). Orphan drug designation is also being sought for bladder cancer patients with specific genetic alterations.

Mirati Therapeutics - 08/11/2014

Mirati Therapeutics Receives Orphan Drug Designation from U.S. Food & Drug Administration for Mocetinostat in Myelodysplastic Syndrome

SAN DIEGO, June 17, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that mocetinostat, the company's spectrum selective HDAC inhibitor, has been granted Orphan Drug Designation by the U.S. Food & Drug Administrationas a treatment for myelodysplastic syndrome (MDS). Mocetinostat is being developed in Phase 2 clinical studies in combination with Vidaza as a treatment for intermediate and high-risk MDS, as well as a single agent treatment in patients with diffuse large B-cell lymphoma (DLBCL) and bladder cancer targeting specific genetic mutations in histone acetylation that increase the likelihood of response in tumor cells.

Mirati Therapeutics - 06/17/2014

Mirati Therapeutics and MethylGene Announce Completion of Plan of Arrangement

Mirati Therapeutics Begins Operations

San Diego, California and Montreal, Canada, June 28, 2013 – MethylGene Inc. (“MethylGene”) (TSX:MYG) and Mirati Therapeutics Inc. (“Mirati Therapeutics”) today announced the successful completion, effective June 28, 2013, of the previously announced plan of arrangement (the “Arrangement”), whereby, among other things, MethylGene would migrate to the State of Delaware in the United States of America. Under the Arrangement, Mirati Therapeutics, a holding company, has become the ultimate parent corporation of MethylGene and its subsidiaries. Each MethylGene shareholder received one share of Mirati Therapeutics common stock (“Mirati Share”) for every 50 common shares of MethylGene held, having the effect of a 1 for 50 reverse split. In addition, all outstanding warrants and options have become exerciseable for Mirati Shares and the exercise price and the number of common shares issuable thereunder have been proportionately adjusted to reflect the 1 for 50 effective reverse split. The Mirati Shares are expected to commence trading on the TSX on July 3, 2013, under the symbol “MYG”.

Mirati Therapeutics - 06/28/2013

MethylGene Announces Encouraging Data from Phase 1 Tumor Study

June 25, 2012

MethylGene Inc., a biopharmaceutical company, has announced the encouraging clinical data from the company's Phase I Met/VEGFR multi- kinase inhibitor MGCD265 study.

The MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation Phase I study provided an interim update on the monotherapy trial 265-101.

Trial 265-101 is an ongoing Phase I, multicenter, open-label trial. In this trial patients are treated with MGCD265 alone, dosed orally every day over a 21 day cycle. Data was presented on 57 patients with advanced metastatic or unresectable solid malignancies that were refractory to standard therapy and/or unlikely to derive clinical benefit from existing therapies.

In an ex vivo system designed to assess the biological activity of MGCD265 using plasma samples from study patients, increased plasma concentration of MGCD265 was associated with inhibition of Met phosphorylation in a dose-dependent manner, suggesting coverage of the biological target, Met, in the clinical setting.

Mirati Therapeutics - 06/25/2012

Methylgene announces the initiation of a Phase 2 trial of MGCD0103

Montreal, Quebec. June 25, 2008 – MethylGene Inc. (TSX: MYG) announced today the initiation of a Phase II clinical trial (Trial 013) evaluating MGCD0103, an isoform-selective histone deacetylase (HDAC) inhibitor product candidate, in combination with Vidaza(R) (azacitidine for injection), a DNA demethylating agent, in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).

Mirati Therapeutics - 06/25/2008

MethylGene initiates Phase 1 clinical trial for its multi-targeted (c-Met) kinase inhibitor, MGCD265, in solid tumor cancers

MGCD265 Targets c-Met, VEGFs, Tie-2 and Ron Receptor Tyrosine Kinases

Initial Compound from Portfolio of Potent Multi-targeted Kinase Inhibitors

Montreal, Quebec. April 16, 2008 – MethylGene Inc. (TSX:MYG) today disclosed preclinical data for MGCD265, an oral, multi-targeted (c-Met) kinase inhibitor for cancer that targets the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. The data were presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.

Mirati Therapeutics - 04/16/2008

Investor Login

Pappas Capital Announces the Passing of…